The FDA has approved a treatment regimen that will allow some patients with HIV infection to trade their daily pills for a once-a-month injection.
Marketed as Cabenuva, the treatment combines the integrase inhibitor cabotegravir and the nonnucleoside reverse transcriptase inhibitor rilpivirine in an injectable formulation. The drug is indicated for adults with HIV whose viral load has been undetectable while taking a stable antiretroviral regimen and who have no history of treatment failure and no resistance to cabotegravir or rilpivirine.
Voelker R. Monthly Injection Is Approved for Patients With HIV. JAMA. 2021;325(9):816. doi:10.1001/jama.2021.1932
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: